Dr Reddy’s Laboratories is agonizingly close to resuming market activities for its generic Suboxone sublingual film product, but recently saw its case to have a mandate confirming the dismissal of a preliminary injunction turned down. In a market update, Suboxone manufacturer Indivior has outlined its plans to combat the imminent threat.
Dr Reddy’s Laboratories, or any other Suboxone (buprenorphine/naloxone) sublingual film abbreviated new drug application (ANDA) filer, will face immediate competition from brand manufacturer Indivior’s authorized generic upon market entry of their ANDA product, the originator has confirmed as part of a trading update.
Indivior has also doubled down on plans to file by 20 December a petition for a rehearing by the original...
Tevogen is looking to accelerate its growth with a major expansion of its headquarters in Warren, New Jersey, more than doubling its footprint to centralize research and development, regulatory, and corporate functions. The new facility will support the company’s evolving initiatives.
As it prepares to complete its $6.7bn merger with Mallinckrodt, Endo has divested its International Pharmaceuticals business – consisting primarily of Canadian specialty firm Paladin Pharma – to Knight Therapeutics.
As UK players face increasing competitive pressures on “vanilla” generics – including potential new market entrants from China – Ben Ellis, Lupin’s UK and Ireland general manager, explains how the company is focusing on more complex opportunities that require a hybrid generic and branded mindset.
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
